Does the media refer more to PACB or TXG?

In the previous week, 10x Genomics had 2 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 12 mentions for 10x Genomics and 10 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.63 beat 10x Genomics' score of 0.37 indicating that Pacific Biosciences of California is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 1 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FTRE or PACB?

In the previous week, Pacific Biosciences of California had 2 more articles in the media than Fortrea. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 8 mentions for Fortrea. Pacific Biosciences of California's average media sentiment score of 0.63 beat Fortrea's score of 0.50 indicating that Pacific Biosciences of California is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BLFS or PACB?

In the previous week, Pacific Biosciences of California had 9 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.76 beat Pacific Biosciences of California's score of 0.63 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PSNL or PACB?

In the previous week, Pacific Biosciences of California had 6 more articles in the media than Personalis. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 4 mentions for Personalis. Pacific Biosciences of California's average media sentiment score of 0.63 beat Personalis' score of 0.06 indicating that Pacific Biosciences of California is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pacific Biosciences of California 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pacific Biosciences of California (PACB) Competitors

$2.54 +0.03 (+1.20%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.53 -0.01 (-0.35%)

As of 10/2/2026 07:59 PM Eastern

Compare

PACB vs. TXG, MRVI, FTRE, BLFS, and PSNL

Should you buy Pacific Biosciences of California stock or one of its competitors? Pacific Biosciences of California's main competitors and comparable companies include 10x Genomics (TXG), Maravai LifeSciences (MRVI), Fortrea (FTRE), BioLife Solutions (BLFS), and Personalis (PSNL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Pacific Biosciences of California compare to 10x Genomics?

Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Pacific Biosciences of California currently has a consensus price target of $1.71, indicating a potential downside of 32.58%. 10x Genomics has a consensus price target of $53.93, indicating a potential downside of 42.32%. Given Pacific Biosciences of California's higher possible upside, equities analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28

In the previous week, 10x Genomics had 2 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 12 mentions for 10x Genomics and 10 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.63 beat 10x Genomics' score of 0.37 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	1 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.7% of 10x Genomics shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	4.93	-$546.38M	-$0.43	N/A
10x Genomics	$642.82M	18.95	-$43.54M	-$0.59	N/A

10x Genomics has a net margin of -12.18% compared to Pacific Biosciences of California's net margin of -82.49%. 10x Genomics' return on equity of -9.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
10x Genomics	-12.18%	-9.33%	-7.30%

Pacific Biosciences of California has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

Summary

10x Genomics beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Pacific Biosciences of California had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 2 mentions for Maravai LifeSciences. Pacific Biosciences of California's average media sentiment score of 0.63 beat Maravai LifeSciences' score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.3% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Maravai LifeSciences has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

Maravai LifeSciences has a net margin of -37.07% compared to Pacific Biosciences of California's net margin of -82.49%. Maravai LifeSciences' return on equity of -15.70% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Maravai LifeSciences currently has a consensus target price of $6.83, indicating a potential downside of 13.50%. Pacific Biosciences of California has a consensus target price of $1.71, indicating a potential downside of 32.58%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Maravai LifeSciences is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

Maravai LifeSciences has higher revenue and earnings than Pacific Biosciences of California. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	11.04	-$130.77M	-$0.52	N/A
Pacific Biosciences of California	$160.01M	4.93	-$546.38M	-$0.43	N/A

Summary

Maravai LifeSciences beats Pacific Biosciences of California on 10 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Pacific Biosciences of California has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.68B	0.71	-$986.20M	-$0.91	N/A
Pacific Biosciences of California	$160.01M	4.93	-$546.38M	-$0.43	N/A

In the previous week, Pacific Biosciences of California had 2 more articles in the media than Fortrea. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 8 mentions for Fortrea. Pacific Biosciences of California's average media sentiment score of 0.63 beat Fortrea's score of 0.50 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

Fortrea presently has a consensus price target of $22.00, indicating a potential upside of 10.00%. Pacific Biosciences of California has a consensus price target of $1.71, indicating a potential downside of 32.58%. Given Fortrea's stronger consensus rating and higher possible upside, equities analysts plainly believe Fortrea is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

Fortrea has a net margin of -3.18% compared to Pacific Biosciences of California's net margin of -82.49%. Fortrea's return on equity of 10.72% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Summary

Fortrea and Pacific Biosciences of California tied by winning 7 of the 14 factors compared between the two stocks.

How does Pacific Biosciences of California compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

BioLife Solutions currently has a consensus target price of $31.38, suggesting a potential downside of 15.88%. Pacific Biosciences of California has a consensus target price of $1.71, suggesting a potential downside of 32.58%. Given BioLife Solutions' stronger consensus rating and higher possible upside, equities research analysts plainly believe BioLife Solutions is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

BioLife Solutions has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioLife Solutions has a net margin of 53.29% compared to Pacific Biosciences of California's net margin of -82.49%. BioLife Solutions' return on equity of 2.70% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

BioLife Solutions has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	18.97	-$4.59M	$1.16	32.16
Pacific Biosciences of California	$160.01M	4.93	-$546.38M	-$0.43	N/A

In the previous week, Pacific Biosciences of California had 9 more articles in the media than BioLife Solutions. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.76 beat Pacific Biosciences of California's score of 0.63 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLife Solutions beats Pacific Biosciences of California on 11 of the 15 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Personalis?

Personalis (NASDAQ:PSNL) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Personalis has higher earnings, but lower revenue than Pacific Biosciences of California. Personalis is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.67M	24.47	-$81.27M	-$1.09	N/A
Pacific Biosciences of California	$160.01M	4.93	-$546.38M	-$0.43	N/A

Pacific Biosciences of California has a net margin of -82.49% compared to Personalis' net margin of -153.84%. Personalis' return on equity of -46.47% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Personalis has a beta of 2.32, indicating that its stock price is 132% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market.

In the previous week, Pacific Biosciences of California had 6 more articles in the media than Personalis. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 4 mentions for Personalis. Pacific Biosciences of California's average media sentiment score of 0.63 beat Personalis' score of 0.06 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Personalis currently has a consensus target price of $14.54, indicating a potential downside of 10.71%. Pacific Biosciences of California has a consensus target price of $1.71, indicating a potential downside of 32.58%. Given Personalis' stronger consensus rating and higher probable upside, equities analysts clearly believe Personalis is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

Personalis beats Pacific Biosciences of California on 9 of the 16 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PACB vs. The Competition

Export

Metric	Pacific Biosciences of California	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$789.51M	$10.57B	$7.14B	$13.18B
Dividend Yield	N/A	1.45%	2.53%	16.78%
P/E Ratio	-5.91	74.99	275.68	26.04
Price / Sales	4.96	459.91	661.92	103.09
Price / Cash	3.18	26.96	77.60	51.75
Price / Book	127.00	6.85	10.93	6.31
Net Income	-$546.38M	$57.48B	$3.51B	$362.16M
7 Day Performance	56.79%	2.53%	-2.00%	-1.66%
1 Month Performance	95.38%	8.43%	-6.15%	-4.50%
1 Year Performance	70.47%	32.93%	7.44%	2.06%

Pacific Biosciences of California Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PACB Pacific Biosciences of California	0.87 of 5 stars	$2.54 +1.2%	$1.71 -32.6%	+77.6%	$789.51M	$159.27M	N/A	485	News Coverage Options Volume High Trading Volume
TXG 10x Genomics	1.5029 of 5 stars	$88.50 +3.3%	$50.60 -42.8%	+659.5%	$11.17B	$642.82M	N/A	1,178	Analyst Forecast
MRVI Maravai LifeSciences	0.7346 of 5 stars	$7.63 +0.4%	$6.83 -10.4%	+166.0%	$1.97B	$185.74M	N/A	415
FTRE Fortrea	2.8145 of 5 stars	$20.06 +0.9%	$22.00 +9.7%	+108.3%	$1.89B	$2.72B	N/A	14,300	News Coverage Analyst Upgrade
BLFS BioLife Solutions	2.4389 of 5 stars	$39.15 +1.7%	$31.38 -19.9%	+44.0%	$1.88B	$96.21M	33.75	155

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PACB) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, MRVI, FTRE, BLFS, and PSNL

How does Pacific Biosciences of California compare to 10x Genomics?

Summary

How does Pacific Biosciences of California compare to Maravai LifeSciences?

Summary

How does Pacific Biosciences of California compare to Fortrea?

Summary

How does Pacific Biosciences of California compare to BioLife Solutions?

Summary

How does Pacific Biosciences of California compare to Personalis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, MRVI, FTRE, BLFS, and PSNL

How does Pacific Biosciences of California compare to 10x Genomics?

Do analysts recommend PACB or TXG?

Does the media refer more to PACB or TXG?

Do institutionals and insiders have more ownership in PACB or TXG?

Which has better earnings & valuation, PACB or TXG?

Is PACB or TXG more profitable?

Which has more volatility and risk, PACB or TXG?

Summary

How does Pacific Biosciences of California compare to Maravai LifeSciences?

Does the media favor MRVI or PACB?

Do insiders and institutionals believe in MRVI or PACB?

Which has more volatility and risk, MRVI or PACB?

Is MRVI or PACB more profitable?

Do analysts prefer MRVI or PACB?

Which has preferable valuation and earnings, MRVI or PACB?

Summary

How does Pacific Biosciences of California compare to Fortrea?

Which has better earnings & valuation, FTRE or PACB?

Does the media favor FTRE or PACB?

Which has more risk and volatility, FTRE or PACB?

Do analysts prefer FTRE or PACB?

Is FTRE or PACB more profitable?

Summary

How does Pacific Biosciences of California compare to BioLife Solutions?

Do analysts recommend BLFS or PACB?

Which has more volatility & risk, BLFS or PACB?

Do insiders and institutionals hold more shares of BLFS or PACB?

Is BLFS or PACB more profitable?

Which has preferable earnings and valuation, BLFS or PACB?

Does the media refer more to BLFS or PACB?

Summary

How does Pacific Biosciences of California compare to Personalis?

Which has stronger earnings & valuation, PSNL or PACB?

Is PSNL or PACB more profitable?

Which has more volatility and risk, PSNL or PACB?

Does the media prefer PSNL or PACB?

Do institutionals & insiders believe in PSNL or PACB?

Do analysts rate PSNL or PACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools